Campath-1H in renal transplantation: The University of Wisconsin experience
SJ Knechtle, LA Fernandez, JD Pirsch, BN Becker… - Surgery, 2004 - Elsevier
Surgery, 2004•Elsevier
BACKGROUND: Immune cell depletion is known to prevent renal allograft rejection and
injury. We evaluated the humanized monoclonal antibody Campath-1H (alemtuzumab; ILEX
Oncology, San Antonio, Texas) in renal transplant recipients for its safety and efficacy in
preventing rejection when used in combination with a calcineurin inhibitor, mycophenolate
mofetil, and low-dose steroid therapy. METHODS: One hundred twenty-six consecutive renal
allograft recipients received 2 doses of Campath-1H antibody on days 0 and 1. Outcomes …
injury. We evaluated the humanized monoclonal antibody Campath-1H (alemtuzumab; ILEX
Oncology, San Antonio, Texas) in renal transplant recipients for its safety and efficacy in
preventing rejection when used in combination with a calcineurin inhibitor, mycophenolate
mofetil, and low-dose steroid therapy. METHODS: One hundred twenty-six consecutive renal
allograft recipients received 2 doses of Campath-1H antibody on days 0 and 1. Outcomes …
BACKGROUND
Immune cell depletion is known to prevent renal allograft rejection and injury. We evaluated the humanized monoclonal antibody Campath-1H (alemtuzumab; ILEX Oncology, San Antonio, Texas) in renal transplant recipients for its safety and efficacy in preventing rejection when used in combination with a calcineurin inhibitor, mycophenolate mofetil, and low-dose steroid therapy.
METHODS
One hundred twenty-six consecutive renal allograft recipients received 2 doses of Campath-1H antibody on days 0 and 1. Outcomes were compared to patients who received an anti-CD25 antibody (n=799), Thymoglobulin (n=160), or other antibody treatment (n=156) in combination with a calcineurin inhibitor, mycophenolate mofetil, and higher dose steroids.
RESULTS
The Campath-1H group overall experienced less rejection than the other 3 groups (P=.037). Patients with delayed graft function experienced less rejection with Campath-1H than control groups (P=.0096) and improved graft survival (P=.0119). There was no difference in infection or malignancies between the 4 groups.
CONCLUSIONS
Campath-1H was well tolerated in renal transplant patients and led to significant reductions in incidence of rejection. Patients with delayed graft function experienced significantly improved graft survival.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果